| Enanta Pharmaceuticals is a biotechnology company that engaged in the discovery and development of small molecule drugs for the treatment of viral infections. Co.'s primary wholly-owned research and development programs are in virology, namely respiratory syncytial virus, severe acute respiratory syndrome coronavirus 2, hepatitis B virus and human metapneumovirus. Co.'s out-licensed products include two protease inhibitors, which are developed through Co.'s Collaborative Development and License Agreement with AbbVie have been clinically tested, manufactured, and commercialized by AbbVie as part of its combination regimens for hepatitis C virus. We show 46 historical shares outstanding datapoints in our coverage of ENTA's shares outstanding history.|
Understanding the changing numbers of ENTA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ENTA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ENTA by allowing them to research ENTA shares outstanding history
as well as any other stock in our coverage universe.